Racial disparities in recurrence among patients with early-stage endometrial cancer is recurrence increased in black patients who receive estrogen replacement therapy?

Cancer

Volumn 113, Issue 6, 2008, Pages 1431-1437

  Maxwelf, G Larry ^a,b,c   Tian, Chunqiao ^a,d   Risinger, John I ^a,e   Hamilton, Chad A ^a,c   Barakat, Richard R ^a,f  

^a A Gynecologic Oncology Group Study

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

^e Curtis and Elizabeth Anderson Cancer Institute   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Gynecologic; Malignancies; Outcome; Race

Indexed keywords

ESTROGEN;

ADULT; AGED; ARTICLE; BODY MASS; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; DEMOGRAPHY; DISEASE FREE SURVIVAL; ENDOMETRIUM CANCER; ESTROGEN THERAPY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RACISM; RETROSPECTIVE STUDY;

ADENOCARCINOMA; AFRICAN AMERICANS; AGED; ENDOMETRIAL NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; HEALTH STATUS DISPARITIES; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 53149091625     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23717     Document Type: Article

References (29)

1. American Cancer Society. Cancer Facts & Figures for African Americans 2005-2006. Atlanta, Ga: American Cancer Society; 2005. Available at: http://www.cancer.org/downloads/STT/CAFF2005AACorrPWSecured.pdf. Accessed on July 11, 2008.
2. Ghafoor A, Jemal A, Cokkinides V, et al. Cancer statistics for African Americans. CA Cancer j Clin. 2002;52:326-341.
3. lemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106-130.
4. Liu JR, Conaway M, Soper IT, et al. Relationship between race and interval to treatment in endometrial cancer. Obstet Gynecol. 1995;86:486-490.
5. Randall TC, Armstrong K. Differences in treatment and outcome between African-American and white women with endometrial cancer. j Clin Oncol. 2003;21:4200-4206.
6. Hicks ML, Phillips JL, Parham G, et al. The National Cancer Data Base report on endometrial carcinoma in African-American women. Cancer. 1998;83:2629-2637.
7. Cossrow N, Falkner B. Race/ethnic issues in obesity and obesity-related comorbidities. j Clin Endocrinol Metab. 2004; 89;2590-2594.
8. Plaxe SC, Saltzstein SL. Impact of ethnicity on the incidence of high-risk endometrial carcinoma. Gynecol Oncol. 1997:65:8-12.
9. Sherman ME, Devesa SS. Analysis of racial differences in incidence, survival and mortality for malignant tumors of the uterine corpus. Cancer. 2003:98:176-186.
10. Maxwell GL, Brown M, Tian C, et al. Racial disparity in advanced endometrial cancer: a Gynecologic Oncology Group study. Cancer. 2006;107;2197-2205.
11. Barakat RR, Bundy BN, Spirtos NM, et al. Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2006;24:587-592.
12. Madison T, Schottenfeld D, James SA, et al. Endometrial cancer: socioeconomic status and racial/ethnic differences in stage at diagnosis, treatment, and survival. Am J Public Health. 2004;94:2104-2111.
13. Trimble EL, Harlan LC, Clegg LX, et al. Preoperative imaging, surgery and adjuvant therapy for women diagnosed with cancer of the corpus uteri in community practice in the United States. Gynecol Oncol. 2005;96:741-748.
14. Modesitt SC, Huang B, Shelton BJ, et al. Endometria] cancer in Kentucky: the impact of age, smoking status, and rural residence. Gynecol Oncol. 2006;103:300-306.
15. Jolly S, Vargas CE, Kumar T, et al. The impact of age on long-term outcome in patients with endometrial cancer treated with postoperative radiation. Gynecol Oncol. 2006; 103:87-93.
16. von Gruenigen VE, Tian C, Frasure H, et al. Treatment effects, disease recurrence, and survival in obese women with early endometrial carcinoma: a Gynecologic Oncology Group Study. Cancer. 2006;107:2786-2791.
17. Creasman WT, Henderson D, Hinshaw W, et al. Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol. 1986;67:326-330.
18. Lee RB. Estrogen replacement therapy following treatment for stage I endometrial carcinoma. Gynecol Oncol. 1990;67: 189-191.
19. Suriano KA, McHale M, McLaren CE, et al. Estrogen replacement therapy in endometrial cancer patients: a matched control study. Obstet Gynecol. 2001;97:555-560.
20. Chapman JA. Estrogen replacement in surgical stage I and II endometrial cancer survivors. Obstet Gynecol 1996;175: 1195-2000.
21. Holinka CF, Hata H, Kuramoto H, et al. Responses to estradiol in a human endometrial adenocarcinoma cell line (Ishikawa). J Steroid Biochem. 1986;24:85-89.
22. Farnell YZ, Ing NH. The effects of estradiol and selective estrogen receptor modulators on gene expression and messenger RNA stability in immortalized sheep endometrial stromal cells and human endometrial adenocarcinoma cells. J Steroid Biochem Mol Biol. 2003;84:453-461.
23. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women Health Initiative randomized controlled trial. JAMA. 2002;288:321-323.
24. Kohler MF, Carney P, Dodge R, et al. p53 Overexpression in advanced-stage endometrial adenocarcinoma. Am J Obstet Gynecol. 1996;175:1246-1252.
25. Santin AD, Bellone S, Siegel ER, et al. Racial differences in the overexpression of epidermal growth factor type II receptor (Her-2/neu): a major prognostic indicator in uterine serous papillary cancer. Obstet Gynecol. 2005;192:813-818.
26. Maxwell GL, Risinger JI, Hayes KA, et al. Racial disparity in the frequency of PTEN mutations, but not microsatellite instability, in advanced endometrial cancers. Clin Cancer Res. 2000;6:2999-3005.
27. Clifford SL, Kaminetsky CP, Cirisano FD, et al. Racial disparity in overexpression of the p53 tumor suppressor gene in stage I endometrial cancer. Am J Obstet Gynecol. 1997; 176:S229-S232.
28. Rebbeck TR, Troxel AB, Wang Y, et al. Estrogen sulfation genes, hormone replacement therapy, and endometrial cancer risk. J Natl Cancer Inst. 2006;98:1311-1320.
29. Jones DA, Cho J, Salamon E, Stefano GB. Risk factors for breast cancer and the prognosis of African American women: estrogen's role. Med Sci Monit. 2003;9:RA131-RA139.